ライフサイエンスコーパス: haemopoietic

1 Novel analogues of EPO are devoid of haemopoietic activity but still possess protective prope

2 questions the significance of studies in non-haemopoietic and differentiation blocked haemopoietic ce

3 eadily reverted the transformed phenotype of haemopoietic and fibroblast cell lines that express the

4 (siglecs) are expressed predominantly in the haemopoietic and immune systems and exhibit specificitie

5 enile and adult life, spanning the skeletal, haemopoietic and immune systems.

6 Autologous CD34-positive haemopoietic bone-marrow stem cells were transduced ex v

7 f the kinase domain, potently transforms the haemopoietic cell line FDC-P1 yet prevents Rat-2 fibrobl

8 ure sensitive Bcr-Abl PTK in the multipotent haemopoietic cell line FDCP-Mix for short periods result

9 By transfecting the multipotent haemopoietic cell line FDCP-Mix with a temperature sensi

10 okine showed any similarities, we employed a haemopoietic cell line, TonB210, engineered for inducibl

11 ical role played by mTORC1 in regulating the haemopoietic cell lineage commitment.

12 cripts were assayed in human umbilical blood haemopoietic cell lineages.

13 Very few maternal cells expressed the haemopoietic cell marker CD45.

14 In addition to flow cytometric analyses of haemopoietic cell markers, we analysed the hES cell-deri

15 The CD45 antigen is a haemopoietic cell specific tyrosine phosphatase essentia

16 with multiple myeloma undergoing autologous haemopoietic cell transplantation (auto-HCT).

17 The success of unrelated haemopoietic cell transplantation (HCT) is limited by gr

18 Allogeneic donor CCR5 Delta32 homozygous haemopoietic cell transplantation (HCT) provides the onl

19 nt relapse is the overall goal of allogeneic haemopoietic cell transplantation (HCT).

20 de dosing improves outcomes after allogeneic haemopoietic cell transplantation (HCT).

21 ty) conditioning preparative regimens before haemopoietic cell transplantation from an unrelated dono

22 onic graft-versus-host disease (CGVHD) after haemopoietic cell transplantation from an unrelated dono

23 ical and laboratory data of patients who had haemopoietic cell transplantation from Jan 1, 1991, to D

24 Haemopoietic cell transplantation is established as a st

25 Allogeneic haemopoietic cell transplantation substantially reduces

26 Studies with autologous and allogeneic haemopoietic cell transplantation suggest that HIV statu

27 nd non-myeloblative preparative regimens for haemopoietic cell transplantation when using unrelated d

28 ts undergoing myeloablative conditioning and haemopoietic cell transplantation would have different m

29 CD45, the leucocyte common antigen, is a haemopoietic cell-specific tyrosine phosphatase.

30 Haemopoietic-cell transplantation (HCT) is an intensive

31 Secretory lysosomes are common to many other haemopoietic cells and also melanocytes.

32 ranscription factor is expressed in immature haemopoietic cells and at key stages during differentiat

33 ourth human chemokine type, derived from non-haemopoietic cells and bearing a new CX3C fingerprint.

34 ll markers, we analysed the hES cell-derived haemopoietic cells by colony-forming assays (for erythro

35 tnatal human neuropoiesis happens, and human haemopoietic cells can transdifferentiate into neurons,

36 Transplantable human haemopoietic cells could serve as a therapeutic source f

37 ablishing chimeric engraftment in hosts with haemopoietic cells derived from an existing hES cell lin

38 eloped a method to generate a broad range of haemopoietic cells from hES-generated embryonic bodies i

39 ory mechanism to transformation of primitive haemopoietic cells is abrogation of response to a growth

40 ned with conditional knockout of SIK3 in the haemopoietic cells resulted in a severe reduction in per

41 tion of GATA transcription factors in murine haemopoietic cells was examined by indirect immunofluore

42 Conditional knockout of SIK3 in haemopoietic cells, driven by a Vav-iCre transgene, resu

43 ds to efficiently differentiate hES cells to haemopoietic cells, including immune-modulating leucocyt

44 K) in their blast cells compared with normal haemopoietic cells, rendering the cells sensitive to the

45 rucial to the development and functioning of haemopoietic cells, so much so that mouse embryos homozy

46 sion of apoptosis by this cytokine in normal haemopoietic cells.

47 non-haemopoietic and differentiation blocked haemopoietic cells.

48 this increased abl PTK activity in primitive haemopoietic cells.

49 could occur without excessive GVHD in mixed haemopoietic chimeras produced across HLA barriers with

50 Mixed haemopoietic chimerism was established, with a predomina

51 lling theoretical reasons why treatment with haemopoietic colony-stimulating factors might reduce sep

52 We demonstrate a shift in the haemopoietic composition of fetal liver during gestation

53 ies were further cultured in the presence of haemopoietic cytokines.

54 tion of DNA and histones, leading to blocked haemopoietic differentiation.

55 sufficient to accelerate the onset of clonal haemopoietic disorders usually associated with later lif

56 The kinetics of haemopoietic engraftment impose replicative stress on th

57 is, chronic haemolytic anaemia, compensatory haemopoietic expansion, hypercoagulability, and increase

58 raft parenchymal cells; recognition of donor haemopoietic fraction was not required.

59 ll had severely shortened telomeres, reduced haemopoietic function, and raised serum erythropoietin a

60 d aplastic anemia, both typified by impaired haemopoietic function.

61 after the identification of EPO as the major haemopoietic growth factor determining survival and matu

62 n of proliferation and commitment within the haemopoietic hierarchy.

63 proposed to delineate the role of mTORC1 in haemopoietic lineage commitment using knock out (KO) mou

64 stage the absence of c-Myb blocks the adult haemopoietic lineages.

65 Haemopoietic microchimerism has been identified in recip

66 or other ubiquitous (Spl, c-Jun and TBP) or haemopoietic (NF-E2) transcription factors.

67 ght be an example of transdifferentiation of haemopoietic or stromal progenitor cells.

68 Bone marrow transplantation recreated the haemopoietic phenotype of increased circulating M2 macro

69 c-FMS is expressed in pluripotent haemopoietic precursor cells and is subsequently upregul

70 ic beta-cell function (adipsin p=0.0056) and haemopoietic precursor proliferation (stem cell growth f

71 d to acute phase response, oxidative stress, haemopoietic processes, as well as to immune response an

72 Haemopoietic progenitor cell (HPC) transplantation can c

73 (AML) is a heterogeneous clonal disorder of haemopoietic progenitor cells and the most common malign

74 PML-RAR alpha fusion protein of APL renders haemopoietic progenitor cells resistant to Fas-, TNF- an

75 ronic myeloid leukaemia (CML), unlike normal haemopoietic progenitor cells, are resistant to the grow

76 rformed on E8.5 yolk sac cells revealed that haemopoietic progenitors are already defective at this s

77 Selective killing of autologous haemopoietic progenitors by the Vbeta-specific lymphocyt

78 timulating factor, mobilise large numbers of haemopoietic progenitors has resulted in the peripheral

79 Cytotoxic T cells and early haemopoietic progenitors share the expression of a numbe

80 in controlling the development of primitive haemopoietic progenitors the identification of the speci

81 priming of expression begins in multipotent haemopoietic progenitors via GATA-2.

82 h elicits an acute leukaemia by transforming haemopoietic progenitors.

83 activity in T cells are similarly active in haemopoietic progenitors.

84 ) is caused by acquired somatic mutations in haemopoietic progenitors.

85 ironment for the development of T cells from haemopoietic progenitors.

86 on the proliferation and survival of normal haemopoietic progenitors.

87 n at lower doses, must be separated from the haemopoietic properties that occur at clinical doses and

88 ed cord blood progenitor cells to accelerate haemopoietic recovery and reduce infections after chemot

89 However, graft failure-albeit with full host haemopoietic recovery-occurred in 50% of patients.

90 Here we show that the key haemopoietic regulators Ikaros and Aiolos require PBK-me

91 Monitoring of haemopoietic status in BMT recipients as time since BMT

92 that transiently maintains immune cells and haemopoietic stem and progenitor cells in G1 arrest.

93 aemia (CML) arises after transformation of a haemopoietic stem cell (HSC) by the protein-tyrosine kin

94 Chronic myeloid leukaemia is a haemopoietic stem cell disorder, the hallmark of which i

95 mal models, the rhesus macaque and the human haemopoietic stem cell reconstituted mouse.

96 herpes zoster in older adults and autologous haemopoietic stem cell transplant recipients.

97 Infection is a main concern after haemopoietic stem cell transplantation (HSCT) and a majo

98 al pathway to cellular engraftment following haemopoietic stem cell transplantation (HSCT) has histor

99 nt of preparative regimens before allogeneic haemopoietic stem cell transplantation (HSCT) is an unme

100 n (HLA)-matched, unrelated donor, allogeneic haemopoietic stem cell transplantation (HSCT) is associa

101 Center, WA, USA, who received an allogeneic haemopoietic stem cell transplantation between Jan 1, 20

102 Allogeneic haemopoietic stem cell transplantation can be complicate

103 dysplastic syndrome and two who had received haemopoietic stem cell transplantation had either no res

104 ical outcome of autologous non-myeloablative haemopoietic stem cell transplantation in patients with

105 Non-myeloablative autologous haemopoietic stem cell transplantation in patients with

106 Autologous non-myeloablative haemopoietic stem cell transplantation is a method to de

107 tratified by geographical region, allogeneic haemopoietic stem cell transplantation, and active malig

108 of overall mortality in the first year after haemopoietic stem cell transplantation, independent of t

109 licable to more than one lysosomal disorder (haemopoietic stem cell transplantation, pharmacological

110 l load and mortality in the first year after haemopoietic stem cell transplantation.

111 ty was 30.0% (95% CI 26.9-33.0) 1 year after haemopoietic stem cell transplantation.

112 unosuppressive and biological treatments, or haemopoietic stem cell transplantation.

113 tolerability of autologous non-myeloablative haemopoietic stem cell transplantation.

114 ugs used for initial therapy with or without haemopoietic stem cell transplantation.

115 CML) is a clonal disorder of the pluripotent haemopoietic stem cell, the hallmark of which is the con

116 arget of the aberrant immune response is the haemopoietic stem cell, the triggering antigens remain u

117 us infusion of three doses of CD133-positive haemopoietic stem cells (0.2 x 10(6) cells per kg per in

118 host haemopoiesis before venous infusion of haemopoietic stem cells (HSCs).

119 Some patients treated by transplantation of haemopoietic stem cells (peripheral blood or bone marrow

120 -Abl, promotes the inappropriate survival of haemopoietic stem cells by a nonautocrine mechanism in t

121 Transplantation of allogeneic haemopoietic stem cells can cure several non-malignant d

122 Allogeneic transplantation with haemopoietic stem cells from an HLA-matched related dono

123 bone marrow becoming the preferred source of haemopoietic stem cells in autologous, and increasingly

124 Clinical experience from use of adult haemopoietic stem cells in haematology will facilitate a

125 Transplantation of haemopoietic stem cells is an increasingly important app

126 End-organ repair by adult haemopoietic stem cells is under great scrutiny with inv

127 The conditioning regimen for the haemopoietic stem cells was 200 mg per kg cyclophosphami

128 Peripheral blood haemopoietic stem cells were mobilised with 2 g per m2 c

129 We mobilised autologous haemopoietic stem cells with 2.0 g/m2 cyclophosphamide a

130 ect the process (ie, clonal proliferation of haemopoietic stem cells with a mutant phosphatidylinosit

131 on poly(I:C) inoculation, or specifically in haemopoietic stem cells, respectively.

132 engraftment impose replicative stress on the haemopoietic stem cells, resulting in a pronounced agein

133 ctive lymphocytes mediate the destruction of haemopoietic stem cells.

134 role in the mobilisation and homeostasis of haemopoietic stem cells.

135 ts (BMT) involves extensive proliferation of haemopoietic stem cells.

136 The combination had no effect on normal haemopoietic stem cells.

137 anaemia is caused by an intrinsic defect of haemopoietic stem cells; both inherited and acquired for

138 se-intense immune suppression and autologous haemopoietic stem-cell (CD34) infusion.

139 Aplastic anaemia is a rare haemopoietic stem-cell disorder that results in pancytop

140 Autologous CD34 selected haemopoietic stem-cell grafts were collected after mobil

141 INTERPRETATION: G-CSF with or without haemopoietic stem-cell infusion did not improve liver dy

142 fficacy of immune suppression and autologous haemopoietic stem-cell infusion to treat such patients.

143 locyte colony-stimulating factor (G-CSF) and haemopoietic stem-cell infusions in patients with liver

144 High-dose chemotherapy with haemopoietic stem-cell rescue improves event-free surviv

145 loablation (with 200 mg/m2 of melphalan) and haemopoietic stem-cell rescue.

146 associated with a uniform reduced intensity haemopoietic stem-cell transplant (HSCT) regimen for chi

147 previous bendamustine-containing regimen, or haemopoietic stem-cell transplant were also excluded.

148 -depleting antibodies followed by autologous haemopoietic stem-cell transplantation (aHSCT), has been

149 omegalovirus (CMV) and undergoing allogeneic haemopoietic stem-cell transplantation (HCT) are at risk

150 ry acute myeloid leukaemia before allogeneic haemopoietic stem-cell transplantation (HCT).

151 antation collected data for the evolution of haemopoietic stem-cell transplantation (HSCT) activity a

152 Autologous haemopoietic stem-cell transplantation (HSCT) benefits p

153 Haemopoietic stem-cell transplantation (HSCT) eradicates

154 Autologous haemopoietic stem-cell transplantation (HSCT) improves s

155 In chronic granulomatous disease allogeneic haemopoietic stem-cell transplantation (HSCT) in adolesc

156 Non-randomised studies of haemopoietic stem-cell transplantation (HSCT) in systemi

157 (GVHD) is the major limitation of allogeneic haemopoietic stem-cell transplantation (HSCT), for which

158 virus-seropositive patients after allogeneic haemopoietic stem-cell transplantation (HSCT), mainly du

159 his trial and after treatment and subsequent haemopoietic stem-cell transplantation (HSCT).

160 plication that occurs in children undergoing haemopoietic stem-cell transplantation (HSCT).

161 cancer and those who have had an allogeneic haemopoietic stem-cell transplantation (HSCT).

162 se of non-relapse mortality after allogeneic haemopoietic stem-cell transplantation (SCT).

163 n, relapse within 12 months after allogeneic haemopoietic stem-cell transplantation [HSCT], or no res

164 Patients proceeding to haemopoietic stem-cell transplantation after quizartinib

165 andidates for reduced-intensity conditioning haemopoietic stem-cell transplantation and had an availa

166 our-infiltrating lymphocytes, and allogeneic haemopoietic stem-cell transplantation for cancer treatm

167 upportive care should improve the success of haemopoietic stem-cell transplantation for high-risk pat

168 with intensive chemotherapy, with or without haemopoietic stem-cell transplantation in first complete

169 therapy, and to assess the effectiveness of haemopoietic stem-cell transplantation in patients with

170 related-donor reduced-intensity conditioning haemopoietic stem-cell transplantation is safe and is as

171 Allogeneic haemopoietic stem-cell transplantation is the only exist

172 g, twice a day) was initiated 10 days before haemopoietic stem-cell transplantation until day 100.

173 standard therapy with or without allogeneic haemopoietic stem-cell transplantation were randomly ass

174 r quizartinib could resume quizartinib after haemopoietic stem-cell transplantation.

175 ) units provide the potential for successful haemopoietic stem-cell transplantation.

176 or prevention of GVHD in broader settings of haemopoietic stem-cell transplantation.

177 ophils and platelets at expected times after haemopoietic stem-cell transplantation.

178 related-donor reduced-intensity conditioning haemopoietic stem-cell transplantation.

179 to more widespread application of allogeneic haemopoietic stem-cell transplantation.

180 Even patients with unrelated donor haemopoietic stem-cell transplants had adequate engraftm

181 Lentiviral vector-mediated haemopoietic stem/progenitor cell (HSPC) gene therapy is

182 with suitable donors are offered allogeneic haemopoietic-stem-cell transplant.

183 derstanding of the roles of c-Myb beyond the haemopoietic system and to our knowledge and means of in

184 n in proliferative deficiencies of the human haemopoietic system, and discuss the potential use of te

185 ve multi- and uni-lineage progenitors of the haemopoietic system.

186 ronchus, trachea, bladder, and lymphatic and haemopoietic systems was lowered.

187 m antigen-specific lymphocyte attack against haemopoietic tissue, we analysed effector immunity, seek

188 Haemopoietic tissues exposed to ionizing radiation are s

189 or myeloid lineage can be detected in adult haemopoietic tissues.

190 tive donor stem-cell engraftment without non-haemopoietic toxicity.

191 GATA-1 is a key haemopoietic transcription factor whose activity is incr